No Cows, No Problem: FDA Greenlights Fermented Dairy Proteins

Verley wins the world's first FDA clearance for precision-fermented, functionalized dairy proteins, clearing the path to US shelves by 2026

6 Mar 2026

One in eight American adults now takes a GLP-1 drug. They need protein, plenty of it, and they are not fussy about where it comes from, so long as it dissolves cleanly into a shake. That quiet shift in demand helps explain why Verley, a French biotechnology firm, has just become the first company anywhere to receive FDA clearance for dairy proteins made through precision fermentation.

The agency issued its "No Questions" GRAS letter in September 2025, covering two whey protein ingredients produced without animals. The first, a high-purity beta-lactoglobulin, matches the amino acid profile of conventional whey and carries elevated leucine, a draw for sports nutrition. The second is engineered for thermal and pH stability, solving a stubborn problem in ready-to-drink beverages: proteins that fall apart when heat-processed.

The ruling matters well beyond one firm's prospects. Until now, the absence of a clear FDA pathway for precision-fermented dairy ingredients had kept many food manufacturers on the sidelines. That ambiguity has narrowed considerably. Ingredient buyers and formulators have, for the first time, a working template to follow.

Capital has taken notice. In late February 2026, Verley closed an oversubscribed $38m Series A round led by Alven, with backing from Bpifrance and Sofinnova among others. The company intends to begin shipping commercial volumes to American customers by late 2026, working through co-manufacturers as it scales production. Stephane Mac Millan, the co-founder and chief executive, confirmed that regulatory filings for the EU and the Middle East are also under way.

Yet sceptics will note that regulatory clearance and commercial traction are different things. Precision fermentation has long promised to reshape the protein market; delivering on that promise at scale, at a competitive cost, remains unproven. The target segments (performance nutrition, active ageing, high-protein beverages) are growing briskly, but they are also crowded. Incumbents in conventional dairy are not standing still.

What Verley has won is not a market. It is a door. Walking through it will require persuading formulators that fermented whey can match the price, reliability and taste of the proteins they already know. In food, novelty is easy. Habit is hard.